Detalhe da pesquisa
1.
Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial.
BMC Cardiovasc Disord
; 23(1): 175, 2023 03 31.
Artigo
Inglês
| MEDLINE | ID: mdl-37003987
2.
Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids.
Clin Endocrinol (Oxf)
; 87(3): 249-256, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28500659
3.
Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial.
Diabetes Metab
; 47(4): 101190, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32919068
4.
Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes: Data From the MIRAD Trial.
JACC Heart Fail
; 9(8): 550-558, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34325885
5.
The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes.
Diabetes
; 70(1): 196-203, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33055188
6.
Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation.
ESC Heart Fail
; 6(5): 983-991, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31429530